准表皮生长因子受体 - - 我们是否错过了目标?
Janet E Dancey1, Boris Freidlin
1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA.
表皮生长因子受体 (EGFR) 抑制剂在癌症治疗中表现有前途. 需要进一步的研究来确定可能对EGFR抑制剂产生反应的患者亚组,并优化治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常的表皮生长因子受体 (EGFR) 信号驱动癌症的扩散,迁移,入侵和血管生成.
- EGFR是癌症治疗药物的验证标,单克隆抗体和小分子在临床开发中.
- 临床前数据表明EGFR抑制剂会抑制瘤生长,并与标准疗法产生协同作用.
研究的目的:
- 审查EGFR在癌症中的作用和EGFR抑制剂的治疗潜力.
- 讨论EGFR抑制剂的临床开发,包括用于非小细胞肺癌 (NSCLC) 的gefitinib.
- 确定未来的研究方向,以优化EGFR抑制剂治疗.
主要方法:
- 对EGFR抑制剂的临床前和临床研究的综述.
- 对gefitinib在NSCLC中的批准和试验数据的分析.
- 讨论EGFR向疗法的挑战和未来研究需求.
主要成果:
- EGFR抑制剂耐受性良好,并在早期临床试验中显示出抗瘤活性.
- 格菲提尼布 (Iressa) 已被批准用于先前接受化疗的高级NSCLC患者,耐药性疾病的响应率为~10%.
- 随机试验显示,在以前未经治疗的NSCLC患者中,当gefitinib添加到化疗时,没有生存益处.
结论:
- EGFR抑制剂代表了一类有前途的向癌症治疗药物.
- 预测性生物标志物对于选择受益于EGFR抑制剂的患者至关重要.
- 需要进一步的临床试验来确定EGFR抑制剂的最佳剂量,时间表和组合.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
相关概念视频
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
